We are
working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients

cell-1
cell-2
cell-3
cell-4
cell-5
cell-6

Pipeline

Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer.

PreclinicalClinicalMarketed
 IndicationProof of PrincipleSafetyDose OptimizationClinical ActivityPivotalCommercial
Heme Malignancies
Emavusertib*
IRAK4
IRAK4-driven Leukemia
(AML/MDS)

TakeAim Leukemia1

Emavusertib*
IRAK4
IRAK4-driven Lymphoma
(NHL, CLL, WM)

TakeAim Lymphoma

Fimepinostat
HDAC/PI3K
MYC-altered Cancers

Immune Checkpoint Inhibitors
CI-8993**
VISTA
VISTA-expressing Cancers

CA-327*
TIM3/PDL1
PDL1/TIM3-expressing Cancers

CA-170*
VISTA/PDL1
PDL1/VISTA-expressing Cancers

Approved Drug
Erivedge***
Hedgehog
Basal Cell Carcinoma

DrugIndicationStage
Heme Malignancies
Emavusertib*
IRAK4
IRAK4-driven Leukemia
(AML/MDS)
Clinical Activity
Emavusertib*
IRAK4
IRAK4-driven Lymphoma
(NHL, CLL, WM)
Clinical Activity
Fimepinostat
HDAC/PI3K
MYC-altered CancersClinical Activity
Immune Checkpoint Inhibitors
CI-8993**
VISTA
VISTA-expressing CancersSafety
CA-327*
TIM3/PDL1
PDL1/TIM3-expressing CancersProof of Principle
CA-170*
VISTA/PDL1
PDL1/VISTA-expressing CancersClinical Activity
Approved Drug
Erivedge***
Hedgehog
Basal Cell CarcinomaCommercial

* IP licensed from Aurigene
** Exclusive option to license IP from ImmuNext
*** IP licensed to Genentech (Curis receives royalty income)

1) In April 2022 the U.S. Food and Drug Administration placed both TakeAim studies (Leukemia and Lymphoma) on partial clinical hold during which no new patients will be enrolled in the studies, and current study participants benefitting from treatment may continue to be treated with emavusertib at doses of 300mg BID or lower.